BiotechTube

Felzartamab + Placebo

Phase 3Recruiting
0 views this week 0 watching⚡ Active
Interest: 44/100
44
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Immunoglobulin A Nephropathy (IgAN)

Conditions

Immunoglobulin A Nephropathy (IgAN)

Trial Timeline

May 8, 2025 → Jun 5, 2029

NCT ID
NCT06935357

About Felzartamab + Placebo

Felzartamab + Placebo is a phase 3 stage product being developed by Biogen for Immunoglobulin A Nephropathy (IgAN). The current trial status is recruiting. This product is registered under clinical trial identifier NCT06935357. Target conditions include Immunoglobulin A Nephropathy (IgAN).

What happened to similar drugs?

0 of 3 similar drugs in Immunoglobulin A Nephropathy (IgAN) were approved

Approved (0) Terminated (0) Active (3)
🔄iptacopanNovartisPhase 3
🔄Rilzabrutinib + Placebo + GlucocorticoidSanofiPhase 3
🔄sparsentan + irbesartan + DapagliflozinTravere TherapeuticsPhase 3

Hype Score Breakdown

Clinical
17
Activity
15
Company
12
Novelty
0
Community
0

Clinical Trials (4)

NCT IDPhaseStatus
NCT07219043Phase 2Recruiting
NCT06935357Phase 3Recruiting
NCT06685757Phase 3Recruiting
NCT05021484Phase 2Completed

Competing Products

11 competing products in Immunoglobulin A Nephropathy (IgAN)

See all competitors
ProductCompanyStageHype Score
ABBV-383 (Etentamig)AbbViePhase 1/2
39
zigakibartNovartisPhase 2
42
iptacopanNovartisPhase 3
47
CCX168AmgenPhase 2
35
InebilizumabAmgenPhase 2
42
Rilzabrutinib + Placebo + GlucocorticoidSanofiPhase 3
47
rilzabrutinib + GlucocorticoidsSanofiPhase 2
35
FelzartamabBiogenPhase 2
32
SparsentanTravere TherapeuticsPhase 2
29
SparsentanTravere TherapeuticsPhase 2
33
sparsentan + irbesartan + DapagliflozinTravere TherapeuticsPhase 3
38